Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.
COVID
SARS‐CoV
atopic dermatitis
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
26
12
2020
received:
28
11
2020
accepted:
17
01
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Sections du résumé
BACKGROUND
Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic.
METHODS
A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity.
RESULTS
A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred.
CONCLUSIONS
Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Identifiants
pubmed: 34152613
doi: 10.1111/all.14767
pmc: PMC8014537
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1813-1824Investigateurs
Giacomo Caldarola
(G)
Dionisio Silvaggio
(D)
Annunziata Dattola
(A)
Maddalena Napolitano
(M)
Silvia Mariel Ferrucci
(SM)
Giacomo Dal Bello
(G)
Tommaso Bianchelli
(T)
Chiara Rovati
(C)
Flavia Pigliacelli
(F)
Michela Ortoncelli
(M)
Katharina Hansel
(K)
Giulia Calabrese
(G)
Camilla Loi
(C)
Michela Iannone
(M)
Federica Veronese
(F)
Paolo Romita
(P)
Greta Tronconi
(G)
Francesca Caroppo
(F)
Giovanna Tilotta
(G)
Alvise Sernicola
(A)
Maria Esposito
(M)
Francesca Raponi
(F)
Giulio Gualdi
(G)
Giulia Rech
(G)
Maria Letizia Musumeci
(ML)
Steven Paul Nisticò
(SP)
Alessio Campitiello
(A)
Laura Bonzano
(L)
Viviana Piras
(V)
Informations de copyright
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
J Dermatolog Treat. 2020 Aug 4;:1-5
pubmed: 32705945
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e433-e434
pubmed: 32339362
Br J Dermatol. 2020 Aug;183(2):404-406
pubmed: 32348554
J Am Acad Dermatol. 2020 Sep;83(3):e251-e252
pubmed: 32534081
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242
pubmed: 32223003
J Am Acad Dermatol. 2020 Aug;83(2):e165-e167
pubmed: 32405123
JAMA Dermatol. 2020 Feb 1;156(2):131-143
pubmed: 31876900
J Dermatolog Treat. 2020 Jun 19;:1-2
pubmed: 32419563
Allergy. 2020 Nov;75(11):2764-2774
pubmed: 32500526
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e368
pubmed: 32386431
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e773-e776
pubmed: 32780487
Dermatol Ther. 2020 Nov;33(6):e14204
pubmed: 32829511
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e303-e304
pubmed: 32330323
Am J Clin Dermatol. 2019 Jun;20(3):443-456
pubmed: 31066001